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Abstract
Background: Cardiac failure secondary to transfusional iron overload is the most common cause of death in patients with thalassemia. Early 
detection of myocardial iron deposition is necessary to prevent overt heart failure. Objective: Assessment of myocardial and hepatic iron 
deposition by T2* weighted magnetic resonance (MR). Materials and Methods: A total of 32 transfusion dependent thalassemic children 
were enrolled in a cross-sectional study conducted at thalassemia center in a teaching hospital. Gradient echo T2* MR was done in all patients 
for the assessment of myocardial and hepatic iron deposition. Results: Out of these 32 thalassemic patients studied, 21 (65.6%)were males 
and 11 (34.4%)were females. The mean age of the enrolled patients was 14.6 years (range 9-24 years). Out of 32 patients studied, cardiac iron 
deposition (cardiac T2* <20 ms)was present in 14 (43.8%)patients and was absent (cardiac T2* >20 ms)in the remaining 18 (56.3%)patients. 
The hepatic iron deposition was assessed by T2* MR in 31/32 patients. None of the patients had normal liver iron (hepatic T2* - more than 
6.3 ms). Out of those 31 patients, 1 (3.2%)patients had mild (hepatic T2* - 6.3-2.7 ms), 17 (54.83%)patients had moderate (hepatic T2* - 2.7-
1.4 ms), and 13 (41.93%)patients had severe (hepatic T2* - <1.4 ms)hepatic iron deposition. No significant correlation could be found 
between hepatic and cardiac T2* (p=0.415, Cramer’s V 0.313). The mean serum ferritin was 5202 ng/ml. No significant association was 
found between cardiac T2* and serum ferritin levels (p=0.270, Cramer’s V 0.350). Conclusion: There is no significant correlation between 
hepatic and cardiac iron deposition. Similarly, no correlation was seen between cardiac iron deposition and serum ferritin levels.
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Thalassemias are a group of chronic, inherited anemias characterized by defective hemoglobin synthesis and ineffective erythropoiesis. Patients with these disorders 
require blood transfusions at regular intervals throughout their 
lives to eliminate the ensuing anemia and compensatory bone 
marrow expansion. However, this treatment causes inexorable 
accumulation of iron in tissues, which, without the treatment, 
leads to congestive heart failure and is usually fatal in the 
second decade of life [1].
The heart failure due to myocardial iron overload remains 
the leading cause of death in patients with transfusion-
dependent anemias. Iron overload-induced cardiomyopathy is 
reversible if intensive chelation therapy is instituted on time. 
Once heart failure develops and left ventricular function is 
reduced, the prognosis is poor [2]. Therefore, early detection 
of myocardial iron deposition is imperative to prevent overt 
heart failure.
Iron is usually stored in the human body as crystalline iron 
oxide within ferritin or as hemosiderin. A magnetic resonance 
imaging (MRI)detects iron indirectly, by the paramagnetic 
effects of stored iron in the form of ferritin and hemosiderin. 
Interaction with nearby hydrogen nuclei in tissue water 
produces changes in the MR signal intensity, susceptibility 
variability and shortens relaxation times T1, T2, and T2*. 
Anderson et al. first reported the utility of T2* imaging in 
detecting myocardial iron content [3]. The T2* relaxation 
time is measured by summation of tissue relaxation (T2)
and magnetic inhomogeneity known as T2 prime (T2’)and 
expressed as (1/T2* = 1/T2 + 1/T2’). Normal cardiac T2* 
values range from 52±16 ms (applicable only to 1.5 Tesla 
scanners). Cardiac MRI gradient echo T2* technique is a 
highly sensitive, non-invasive, diagnostic modality that can 
detect myocardial iron deposition [3].
Myocardial iron overload cannot be predicted from 
serial measurements of serum ferritin or liver iron 
content. Conventional assessment of cardiac function by 
electrocardiography, echocardiography only detects advanced 
cardiac disease [4,5]. T2* weighted cardiac MR (CMR)is the 
gold standard investigation for early detection of cardiac iron 
overload [3].
The present study is undertaken to assess the cardiac iron 
deposition by T2* weighted MR and its correlation with 
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hepatic iron deposition and serum ferritin levels in patients with 
transfusion-dependent thalassemia.
MATERIALS AND METHODS
The present prospective study was conducted at thalassemia 
center in Lokmanya Tilak Municipal Medical College, Sion, 
Mumbai, India. A total of 32 transfusion dependent thalassemic 
patients were enrolled in the present study. Approval from 
Institutional Ethical Committee was taken and informed 
consent from patients or parents (for patients <18 years old)
was obtained. Thalassemic children >7 years of age who 
were on regular blood transfusions administered at 2-4 weeks 
intervals to maintain pre-transfusion hemoglobin above 
9 g/dl and received blood transfusions for minimum 5 years, 
irrespective of presence or absence of a congestive cardiac 
failure (CCF)were included in the study. Thalassemic children 
with congenital cardiac defects and those with claustrophobia 
were excluded.
All the enrolled patients were subjected to detailed history, 
clinical examination, estimation of serum ferritin levels and 
gradient echo T2* MR for the assessment of myocardial and 
hepatic iron deposition. The area measured for myocardial iron 
assessment was interventricular septum. Gradient echo T2* 
MR was performed using 1.5T Sonata scanner from Siemens 
by a single breath hold technique and cardiac T2* and liver T2* 
measurements were noted [3,6].
The data obtained were analyzed using the SPSS 15.0 
software by applying Chi-square test. A p<0.05 was considered 
statistically significant. The strength of association between 
the two variables was measured by Cramer’s V. Cramer’s V 
ranges from 0 to 1. The strength of association increases from 
0 toward 1 [7].
RESULTS
Out of 32 thalassemic patients studied, 21 (65.6%) were males 
and 11 (34.4%) were females. The mean and median age of 
the enrolled patients was 14.6 years and 14 years, respectively 
(range 9-24 years). Out of 32 patients studied, cardiac iron 
deposition (cardiac T2* <20 ms) was present in 14 (43.8%)
patients and was absent (cardiac T2* >20 ms)in the remaining 
18 (56.3%) patients. The mean cardiac T2* was 24.05 ms 
(range 3.6-57 ms). Among the 14 patients having cardiac iron 
deposition, 8 patients had mild (cardiac T2* between 12 and 20 
ms), 1 had moderate (cardiac T2* between 8 and 12 ms) and 5 
had severe (cardiac T2* <8 ms) cardiac iron deposition.
Fig. 1 shows a correlation of age with cardiac iron 
deposition detected by T2* MR. The number of patients 
showing cardiac iron deposition and the severity of the same 
was found to increase with the age as shown in Fig. 1. All the 
5 patients having signs of CCF on clinical examination had 
severe cardiac iron deposition (cardiac T2* <8 ms). There was 
a strong association between severe cardiac iron deposition and 
signs of CCF (p=0.0001, Cramer’s V 1.000).
None of the patients had serum ferritin value <1000 ng/ml. 
10 out of 32 (31.25%)patients had serum ferritin values between 
1000 and 2500 ng/ml and remaining 22/32 (68.75%) patients 
were having serum ferritin values more than 2500 ng/ml. Out 
of 10 patients having serum ferritin values between 1000 and 
2500 ng/ml, cardiac iron deposition was present in 3 (30%)
patients and out of 22 patients having serum ferritin values 
more than 2500 ng/ml, cardiac iron deposition was present in 
11 (50%) patients. The mean serum ferritin was 5202±3546 ng/
ml. No significant association was found between cardiac T2* 
and serum ferritin levels (p=0.270. Cramer’s V 0.350)as shown 
in Fig. 2.
Hepatic T2* was noted in 31/32 patients due to technical 
difficulty in 1 patient. Out of these, 1 (3.2%) patient had 
mild (hepatic T2* - 6.3-2.7 ms), 17 (54.83%)had moderate 
(hepatic T2* - 2.7-1.4 ms)and 13 (41.93%) had severe (hepatic 
T2* - <1.4 ms) hepatic iron deposition. None of the patients 
had normal liver iron (hepatic T2* >6.3 ms).
One patient having mild hepatic iron deposition had no 
cardiac iron deposition. Out of 17 patients with moderate 
hepatic iron deposition, 6 (35.3%) had a cardiac iron deposition. 
Of these 6 patients, 5 had mild, and 1 had a severe cardiac 
iron deposition. Out of 13 patients having severe hepatic iron 
deposition, 8 (61.5%) had cardiac iron deposition. Of these 
8 patients, 3 had mild, 1 had moderate, and 4 patients had severe 
cardiac iron deposition. In our study, no significant correlation 
could be found between hepatic T2* and cardiac T2* (p=0.415, 
Cramer’s V 0.313) as shown in Fig. 3. Fig. 4 depicts the 
discordance between cardiac and hepatic iron deposition [3].
DISCUSSION
The mainstay of therapy in β-thalassemia major is transfusion 
therapy. However, due to multiple red cell transfusions, excess 
iron is deposited in various organs including the heart. Cardiac 
complications represent significant morbidity and remain the 
Figure 1: Correlation of age with cardiac iron deposition
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leading cause of mortality in transfusion-dependent thalassemia 
patients[8]. Conventional cardiac monitoring, including 
physical examination, electrocardiography, echocardiography, 
or serum ferritin levels fail to predict manifest or subclinical 
myocardial involvement resulting from iron overload [4,5]. The 
cardiovascular MRI T2* correlates well with myocardial iron 
levels[9]. This study also showed the association of myocardial 
iron overload and CCF in multiply transfused thalassemic 
patients.
Mavrogeni et al. compared myocardial iron deposition 
assessed by CMR with cardiac biopsy data in 25 patients and 
concluded that heart T2 relaxation time appears in agreement 
with cardiac biopsy, both in high and low iron deposition and 
is a useful non-invasive index in beta thalassemia[10]. Ghugre 
et al. also supported the clinical use of cardiac MRI in iron 
overload syndromes[11]. Casale et al. measured myocardial 
and liver iron overload by T2* multiecho technique in 107 
thalassemia major children and advised the first T2* CMR 
for assessment of cardiac damage as early as feasible to 
tailor chelation treatment[12]. Multislice multiecho T2* MRI 
provides a noninvasive, fast, reproducible means of assessing 
myocardial iron distribution[13]. Quatre et al. also validated 
the application of cardiac MRI to monitor cardiac iron overload 
in patients who have undergone multiple transfusions [14].
In our study, cardiac iron deposition was present in 
14/32 (43.8%)patients. None of the patients under 9 years of 
age demonstrated cardiac iron deposition and all 5 patients with 
severe cardiac iron deposition were more than 19 years of age. 
The number of patients showing cardiac iron deposition and 
its severity was found to increase with the age of the patients. 
Similar results were observed in a study of 77 thalassemic 
children done by Wood et al. [15]. In their study, no patient 
under 9.5 years of age demonstrated an abnormal cardiac T2* 
(<20 ms)while 24% of patients aged 9.5-15 years and 36% 
of patients aged of 15-18 years had detectable cardiac iron. 
Recently, to determine the optimal initial age of cardiac iron 
screening with MRI T2*, Chen et al. retrospectively reviewed 
cardiac T2* assessments from 102 thalassemia major patients 
(aged 3-32 years)and concluded that cardiac iron overload can 
occur in young thalassemia major patients, even as young as 
5.5 years old [16].
No significant association could be found between cardiac 
T2* and serum ferritin levels. Similar results were found in a 
large cohort of 106 thalassemia patients studied by Anderson et 
al. [3]. Wood et al. [17], Hankins et al. [18], Chacko et al. [19], 
Mavrogeni et al. [10], Eghbali et al. [20] and Konen et al. [21] 
also found similar results that there was no correlation between 
serum ferritin and cardiac T2*. In contrast to our study, Shamsian 
et al found a significant correlation between serum ferritin levels 
and cardiac T2* (p<0. 001) in the study of evaluation of iron 
levels in cardiac and hepatic tissues using MRI T2* in 93 patients 
with β-thalassemia major [22]. In our study, no significant 
correlation could be found between hepatic and cardiac T2*. 
Similar observations were noted in studies done by Anderson et 
al. [3], Di Tucci et al. [23] and Mavrogeni et al. [24].
CONCLUSION
The number of patients showing cardiac iron deposition and 
its severity was found to increase with the age of the patients. 
However, no significant association was found between cardiac 
T2* and serum ferritin level. Similarly, no significant correlation 
was found between hepatic and cardiac iron deposition.
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